Epigenetic drug target deconvolution by mass spectrometry–based technologies

Roberta Noberini; Tiziana Bonaldi

doi:10.1038/s41594-019-0279-x

Epigenetic drug target deconvolution by mass spectrometry–based technologies

Roberta Noberini, Tiziana Bonaldi

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

The identification of the full target spectrum of active molecules, known as target deconvolution, has become an indispensable step during the drug discovery process. It is now achievable thanks to mass spectrometry–based technologies. Here we discuss these approaches in the context of epigenetic drug discovery.

Original language	English
Pages (from-to)	854-857
Number of pages	4
Journal	Nature Structural and Molecular Biology
Volume	26
Issue number	10
DOIs	https://doi.org/10.1038/s41594-019-0279-x
Publication status	Published - Oct 1 2019

ASJC Scopus subject areas

Structural Biology
Molecular Biology

Access to Document

10.1038/s41594-019-0279-x

Cite this

@article{bdea7cd5bf5e47ca96fb0ef158d27f09,

title = "Epigenetic drug target deconvolution by mass spectrometry–based technologies",

abstract = "The identification of the full target spectrum of active molecules, known as target deconvolution, has become an indispensable step during the drug discovery process. It is now achievable thanks to mass spectrometry–based technologies. Here we discuss these approaches in the context of epigenetic drug discovery.",

author = "Roberta Noberini and Tiziana Bonaldi",

year = "2019",

month = oct,

day = "1",

doi = "10.1038/s41594-019-0279-x",

language = "English",

volume = "26",

pages = "854--857",

journal = "Nature Structural and Molecular Biology",

issn = "1545-9993",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Epigenetic drug target deconvolution by mass spectrometry–based technologies

AU - Noberini, Roberta

AU - Bonaldi, Tiziana

PY - 2019/10/1

Y1 - 2019/10/1

N2 - The identification of the full target spectrum of active molecules, known as target deconvolution, has become an indispensable step during the drug discovery process. It is now achievable thanks to mass spectrometry–based technologies. Here we discuss these approaches in the context of epigenetic drug discovery.

AB - The identification of the full target spectrum of active molecules, known as target deconvolution, has become an indispensable step during the drug discovery process. It is now achievable thanks to mass spectrometry–based technologies. Here we discuss these approaches in the context of epigenetic drug discovery.

UR - http://www.scopus.com/inward/record.url?scp=85072926341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072926341&partnerID=8YFLogxK

U2 - 10.1038/s41594-019-0279-x

DO - 10.1038/s41594-019-0279-x

M3 - Article

C2 - 31582842

AN - SCOPUS:85072926341

VL - 26

SP - 854

EP - 857

JO - Nature Structural and Molecular Biology

JF - Nature Structural and Molecular Biology

SN - 1545-9993

IS - 10

ER -

Epigenetic drug target deconvolution by mass spectrometry–based technologies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this